Bioatla, Inc. · NASDAQ:BCAB
Bioatla — ESMO Sarcoma and Rare Cancers 2024
16 slides from Bioatla's conference presentation, March 2024
Slide 1: Results from a Phase 2 Part 1 Trial of Mecbotamab Vedotin (BA3011) in Advanced Refractory Sarcoma
RESULTS FROM A PHASE 2 PART 1 TRIAL OF MECBOTAMAB VEDOTIN (BA3011), A CAB-AXL-ADC, IN PATIENTS WITH ADVANCED REFRACTORY SARCOMA Seth M. Pollack, Anthony P. Conley, William Tap, Chueh-Chuan Yen, John Charlson, Lara E. Davis, Anna Chalmers, Mihaela Druta, Elizabeth T. Loggers, Jaspreet Grewal, Gerald
Slide 2: Declaration of Interests
DECLARATION OF INTERESTS Seth M. Pollack Advisory and consulting fees from Adaptimmune, Bayer, Boehringer Ingelheim, Deciphera, Rain Therapeutics, and SpringWorks
Slide 3: Sarcomas Remain Difficult to Treat
SARCOMAS REMAIN DIFFICULT TO TREAT Limited improvements in overall survival over time for Few agents have efficacy in the treatment of osteosarcoma2 metastatic soft tissue sarcomas1 Selected Phase II Trials in Osteosarcoma2 Years Study Study No. of Patients Agent Response Open A09713 10 Topotecan No
Slide 4: Conditionally Active Biologic (CAB) Technology
CONDITIONALLY ACTIVE BIOLOGIC (CAB) TECHNOLOGY Selective and targeted to widen the therapeutic index Alkaline Healthy Cell Membrane Acidic Cancer Cell Membrane Acidic pH (5.8–6.7) at the cancer cell surface unveils pH 6.8 to >7.4 pH 5.8–6.7 binding sites that are shielded at normal pH (6.8 to >7.4)
Slide 5: Mecbotamab Vedotin (BA3011): A CAB-AXL-ADC
MECBOTAMAB VEDOTIN (BA3011): A CAB-AXL-ADC AXL is expressed in a variety of tumor types, with overexpression associated with metastasis, tumor resistance to chemotherapy, and poor prognosis1,2 CAB-AXL-ADC pH binding inflection point adjusted for CAB-tumor cell target tumor microenvironment selectivi
Slide 6: CAB-AXL-ADC: Phase 1 Results
CAB-AXL-ADC: PHASE 1 RESULTS Durable responses observed among patients with UPS, LMS, and Ewing sarcoma; prospective, phase 2, single-arm UPS trial presently enrolling with data to be reported separately 1. Wilky B, Druta M, Ahnert JR, et al. Poster presented at: Connective Tissue Oncology Society A
Slide 7: Phase 2 Part 1 Open-Label Study Design
PHASE 2 PART 1 OPEN-LABEL STUDY DESIGN Inclusion criteria • ≥12 years of age • AXL-expressing† locally advanced, BA3011 1.8 mg/kg monotherapy Q2W Endpoints Screening unresectable, or period • DCR (objective BA3011 1.8 mg/kg + nivolumab Q2W metastatic sarcoma response or stable End of • Measurable di
Slide 8: Demographics and Baseline Characteristics
DEMOGRAPHICS AND BASELINE CHARACTERISTICS BA3011 monotherapy BA3011 + nivolumab Sarcoma subtypes enrolled (excluding UPS) (n=87) (n=26) Ewing sarcoma Soft tissue n=8 Age, y, mean (SD) BA3011 sarcoma (other) n=21 Overall 51.5 (17.2) 55.3 (12.8) monotherapy 9% Osteosarcoma n=12 24% 12–17 3 (3.4) 0 14%
Slide 9: BA3011 Monotherapy Antitumor Activity
BA3011 MONOTHERAPY ANTITUMOR ACTIVITY 140 DCR* = 37/86 (43.0%) 120 (95% CI, 32.4–54.2) 100 Change in target lesion from baseline (%) 80 60 40 20 0 -20 -40 On treatment Progressive disease -60 Stable disease Partial response -80 0 5 10 15 20 25 30 35 40 45 50 55 60 Time (weeks) • Disease control obse
Slide 10: Osteosarcoma Phase 2 PFS
OSTEOSARCOMA PHASE 2 PFS BA3011 monotherapy 100 Events, n Median, months PFS W12, % 90 (%) (95% CI) (95% CI) 80 11 (83.3) 2.8 (1.2–4.6) 45.5 (16.7–70.7) 70 60 PFS (%) 50 40 30 20 10 0 0 1 2 3 4 5 6 7 Months from first dose Number at risk 12 10 6 4 2 1 0 • Week 12 PFS of 45.5% exceeds COG threshold (
Slide 11: Osteosarcoma Response to BA3011 Monotherapy
OSTEOSARCOMA RESPONSE TO BA3011 MONOTHERAPY 83-year-old man previously treated with liposomal doxorubicin and cabozantinib A B Baseline chest CT with contrast (June 26, 2023) C D Follow-up chest CT with contrast (August 14, 2023) Data cutoff date: November 27, 2023. Abbreviation: CT, computed tomogr
Slide 12: Liposarcoma and Synovial Sarcoma Phase 2 PFS
LIPOSARCOMA AND SYNOVIAL SARCOMA PHASE 2 PFS BA3011 monotherapy Liposarcoma Synovial sarcoma BioAtla Page 1 of 1 100 Protocol: BA3011-001 100 Figure 1.3.1.6.1 Progression -Free Survival by AXL for Patients with BA3011 alone - STS (Synovial) Events, n Median, months PFS W12, % Events, As-treated n Su
Slide 13: Safety Summary
SAFETY SUMMARY Broadly well tolerated; most events low-grade and reversible Most frequent TEAEs (≥15% of patients) Summary of TEAEs BA3011 monotherapy BA3011 + nivolumab Characteristic, n (%) (n=87) (n=26) Any TEAE 85 (97.7) 24 (92.3) Related TEAEs with CTCAE grade 3 or 4* 26 (29.9) 11 (42.3) Relate
Slide 14: Conclusions
CONCLUSIONS • Every-other-week delivery of an AXL-targeted ADC, mecbotamab vedotin, attained disease control in 43% of patients with treatment-refractory sarcomas • Treatment responses were observed among patients with osteosarcoma (2 PRs; week 12 PFS rate = 45.5%) and undifferentiated pleomorphic s
Slide 15: Thank You
THANK YOU MSIESMO SARCOMA AND RARE CANCERS
Slide 16: Sarcomas Remain Difficult to Treat
SARCOMAS REMAIN DIFFICULT TO TREAT Limited improvements in overall survival over time for bone and soft tissue sarcomas1 Kaplan–Meier survival curves by year of diagnosis for Kaplan–Meier survival curves by year of diagnosis for patients with bone sarcomas at a tertiary cancer center patients with s